Condition
Pleural Mesothelioma Malignant Advanced
Estimated Enrollment: 142
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: ETOP 9-15|2016-002062-31|3475-594
Study First Received: December 9, 2016
Last Updated: December 9, 2016
Estimated Primary Completion Date: November 2020
Primary Outcome Measures:
Progression Free Survival (PFS) in patients with advanced pre-treated malignant mesothelioma.|Objective response.|Overall survival.|Time to treatment failure.|Toxicity/adverse events.|Investigator assessed PFS
Sponsors and Collaborators:
European Thoracic Oncology Platform|Merck Sharp & Dohme Corp.|Frontier Science Foundation, Hellas
Website Link: https://ClinicalTrials.gov/show/NCT02991482
